Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Carini

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Frontiers in Pharmacology|February 26, 2019
Hsp60 as a Novel Target in IBD Management: A ProspectFrancesco Cappello, Margherita Mazzola, Abdo Jurjus, et al.
Cancer Letters|November 13, 2016
Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescenceAntonella Marino Gammazza, Claudia Campanella, Rosario Barone, et al.
Current Pharmaceutical Design|October 25, 2012
Hsp60, a novel target for antitumor therapy: structure-function features and prospective drugs designAndrea Pace, Giampaolo Barone, Antonino Lauria, et al.
Biology|May 24, 2024
Nanovesicular Mediation of the Gut-Brain Axis by Probiotics: Insights into Irritable Bowel SyndromeRadha Santonocito, Letizia Paladino, Alessandra Maria Vitale, et al.
Anticancer Research|July 31, 2014
Comparative analysis of Hsp10 and Hsp90 expression in healthy mucosa and adenocarcinoma of the large bowelFrancesca Rappa, Carmelo Sciume, Margherita Lo Bello, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Frontiers in Pharmacology|February 26, 2019
Hsp60 as a Novel Target in IBD Management: A ProspectFrancesco Cappello, Margherita Mazzola, Abdo Jurjus, et al.
Cancer Letters|November 13, 2016
Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescenceAntonella Marino Gammazza, Claudia Campanella, Rosario Barone, et al.
Current Pharmaceutical Design|October 25, 2012
Hsp60, a novel target for antitumor therapy: structure-function features and prospective drugs designAndrea Pace, Giampaolo Barone, Antonino Lauria, et al.
Biology|May 24, 2024
Nanovesicular Mediation of the Gut-Brain Axis by Probiotics: Insights into Irritable Bowel SyndromeRadha Santonocito, Letizia Paladino, Alessandra Maria Vitale, et al.
Anticancer Research|July 31, 2014
Comparative analysis of Hsp10 and Hsp90 expression in healthy mucosa and adenocarcinoma of the large bowelFrancesca Rappa, Carmelo Sciume, Margherita Lo Bello, et al.
Pageof 4